Abstract
Many significant developments in the diagnosis and clinical management of thrombotic disorders have occurred recently [1– 24, 26]. Basic medical sciences have contributed remarkably in both the areas of therapeutics and diagnosis of arterial and venous thrombosis. Many newer approaches for the diagnosis and treatment of thrombotic disorders have been introduced [10, 14, 16]. This has only been possible due to the understanding of the molecular mechanisms involved in the development of thrombotic processes.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Fareed J. Development of heparin fractions. Some overlooked considerations. Semin Thromb Hemostas 11(2), 227–236, 1985.
Fareed J. Heparin, its fractions, fragments and derivatives. Semin Thromb Hemostas 11(1), 1–9, 1985.
Fareed J. New methods in hemostatic testing. In: Fareed J (Ed). Perspectives in hemostasis. New-York, Pergamon Press, pp 310–348, 1981.
Fareed J, Baker WH, Hayes A, Walenga JM. Molecular markers of hemostatic activation in established atherosclerosis. Semin Thromb Hemostas 12(2), 102–109, 1986.
Fareed J, Baker WH, Walenga JM, Messmore HL. Molecular markers of pathophysiological activation of hemostasis: Current perspectives and future trends. In: Ulutin, ON and Vinazzer H (Eds). Thrombosis and hemorrhagic diseases. Istanbul, Turkey, Gozlem Matbaachk Koll. Sto., pp 83–88, 1986.
Fareed J, Bick RL, Squillaci G, Walenga JM, Bermes EWJr. Molecular markers of hemostatic disorders. Implications in the diagnosis and therapeutic management of thrombotic and bleeding disorders. Clin Chem 29(9), 1641–1658, 1983.
Fareed J, Kumar A, Walenga JM, Emanuele RM, Williamson K, Hoppensteadt D. Antithrombotic actions and pharmacokinetics of heparin fragments. Nouv Rev Fr Hematol 26, 267–275, 1984.
Fareed J, Messmore HL, Bermes EWJr. New perspectives in coagulation testing. Clin Chem 26(10), 1380–1891, 1980.
Fareed J, Messmore HL, Walenga JM, Bermes EWJr. Laboratory evaluation of antithrombin III: A critical overview of currently available methods for antithrombin III measurements. Semin Thromb Hemostas 8(4), 288–301, 1983.
Fareed J, Walenga J, Breddin K, Caen JP. Newer avenues in antithrombotic therapy. Semin Thromb Hemostas 15(1&2), 1989.
Fareed J, Walenga JM. Biochemical and pharmacological considerations in the development of heparin and its depolymerized derivatives. Med J Australia 144, 21–30, 1986.
Fareed J, Walenga JM. Current trends in hemostatic testing. Semin Thromb Hemostas 9(4), 379–391, 1983.
Fareed J, Walenga JM, Bick RL, Messmore HL. Low molecular weight markers of hemostatic defects: impact of automation on the quantitation of hemostatic disorders. Semin Thromb Hemostas 9(4), 354–378, 1983.
Hull R, Hirsh J. Long term anticoagulant therapy in patients with venous thrombosis. Arch Int Med, 143, 2061–2063, 1983.
ISIS-2 (Second International Study of Infarct Survival). Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 13, 349–360, 1988.
Lagerstedt CI, Fagher B, Olsson C, Oqvist BW. Need for long-term anticoagulant treatment in symptomatic calf vein thrombosis. Lancet 515–518, 1985.
Markwardt F. Pharmacological approaches to thrombin regulation. Ann NY Acad Sei USA 485, 204–214, 1986.
Markwardt F. Pharmacology of hirudin: One hundred years after the first report of the anticoagulant agent. Biomed Biochim Acta 44, 1007–1013, 1985.
Markwardt F, Fink E, Kaiser B, Klocking HP, Nowak G, Richter M, Sturzebecher J. Pharmacological survey of recombinant hirudin. Pharmazie 43, 202–207, 1988.
Messmore HL, Walenga JM, Fareed J. Molecular markers of platelet activation. Semin Thromb Hemostas 10(4), 264–269, 1984.
Petitti DB, Strom B, Melmon K. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism and hemorrhage. Am J Med 81, 255–259, 1986.
Suarez CR, Fareed J, Tomich P. Neonatal and natural hemostasis: Value of molecular markers in the assessment of hemostastic status. Semin Thromb Hemostas 10(4), 208–284, 1984.
Summaria L, Caprini JA, McMillan R, Sandesara J, Axelrod CA, Mueller ME, Vagher JP, Walenga J, Fareed J. Relationship between post¬surgical fibrinolytic parameters and deep vein thrombosis in surgical patients treated with compression devices. Amer Surgeon 54(3), 156–160, 1988.
Ulutin ON, Fareed J, Kumar A, Walenga JM, Hoppensteadt D. Pharmacologic profiling of the action of defibrotide in animal models of hemostatic and thrombotic disorders. In: Ulutin ON and Vinazzer H (Eds). Thrombosis and hemorrhagic diseases. Istanbul, Turkey. Gozlem Matbaachk Koll. Sto., pp 101–110, 1986.
Walenga JM, Fareed J, Hoppensteadt D, Emanuele RM. Laboratory monitoring of heparin: Old vs. new methods. CRC Critical Review in Lab Sei 22(4), 386–389, 1986.
Walenga JM, Fareed J, Messmore HL. Newer avenues in the monitoring of antithrombotic therapy: The role of automation. Semin Thromb Hemostas 9(4), 346–354, 1983.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag New York, Inc.
About this chapter
Cite this chapter
Fareed, J. (1994). Current trends in antithrombotic drug device development. In: Doutremepuich, C. (eds) Anticoagulation. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-2668-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-4612-2668-0_1
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4612-7627-2
Online ISBN: 978-1-4612-2668-0
eBook Packages: Springer Book Archive